Impact of Maternal Eating Disorders on Pediatric Respiratory Health in Europe
December 10, 2025
Free CME credits
Both our subscription plans include Free CME/CPD AMA PRA Category 1 credits.
Brand Name :
Pluvicto
Synonyms :
lutetium lu 177 vipivotide tetraxetan
Class :
Radiopharmaceuticals
Brand Name :
Pluvicto
Synonyms :
lutetium lu 177 vipivotide tetraxetan
Class :
Radiopharmaceuticals
Dosage Forms & Strengths
Solution for Injection
1000MBq/ml in a single dose vial (27mCi/ml)
Indicated in the treatment of Castration-Resistant Prostate Cancer in people who are treated with taxane chemotherapy and androgen receptor pathway inhibition
7.4 GBq intravenously every 6 weeks up to 6 doses or until the disease is progressed
Indicated in the treatment of Castration-Resistant Prostate Cancer in people who are treated with taxane chemotherapy and androgen receptor pathway inhibition
7.4 GBq intravenously every 6 weeks up to 6 doses or until the disease is progressed
Dose Modifications
If the treatment gets delayed for more than 4 weeks, discontinue the treatment
Reduce the dose by 20% (up to 5.9GBq) once
In the case of 2nd to 3rd-grade myelosuppression, reduce the dose by 20%
For 3rd-grade myelosuppression, discontinue permanently
In the case of renal and hepatic impairment, no dose adjustment is required
Safety and efficacy are not seen in pediatrics
Refer to the adult dosing
Actions and Spectrum:
Actions
lutetium lu 177 is a beta-emitting radionuclide, emitting beta particles during radioactive decay. These beta particles have a short range in tissue (a few millimeters), allowing for localized radiation therapy. The emitted beta particles deposit their energy in the tumor cells, causing DNA damage and ultimately leading to cell death.
lutetium lu 177 vipivotide tetraxetan is primarily used to treat certain neuroendocrine tumors, particularly those originating in the gastroenteropancreatic system. Neuroendocrine tumors express somatostatin receptors, making them suitable targets for this therapy. lutetium lu 177 vipivotide tetraxetan offers a targeted and systemic treatment option for patients with inoperable or metastatic neuroendocrine tumors.
Spectrum
lutetium lu 177 vipivotide tetraxetan has shown promising therapeutic efficacy in managing neuroendocrine tumors.
lutetium lu 177 vipivotide tetraxetan is primarily used palliative treatment as an option for patients with advanced or metastatic neuroendocrine tumors. It aims to alleviate symptoms, such as pain, hormonal excess, and tumor-related complications, and improve the patient’s overall well-being.
Frequency not defined
>10%
Decreased leukocytes (56%)
Decreased calcium (39%)
Decreased lymphocytes (85%)
Decreased hemoglobin (63%)
Nausea (35%)
Decreased platelets (45%)
Fatigue (43%)
Dry mouth (39%)
Increased AST (28%)
Increased potassium (24%)
Decreased sodium (33%)
Anemia (32%)
Decreased appetite (21%)
Decreased neutrophils (28%)
Increased creatinine (24%)
Constipation (20%)
Thrombocytopenia (17%)
Urinary tract infection (12%)
Vomiting (19%)
Diarrhea (19%)
Increased sodium (11%)
Weight loss (11%)
Abdominal pain (11%)
1-10%
Decreased platelets (9%)
Thrombocytopenia (8%)
Decreased neutrophils (4.5%)
Urinary tract infection (3.8%)
Decreased leukocytes (7%)
Fatigue (6%)
Acute kidney injury (3.2%)
Decreased calcium (2.5%)
Constipation (1.1%)
Abdominal pain (1.1%)
Decreased appetite (1.9%)
Nausea (1.3%)
Increased AST (1.1%)
Black Box Warning:
None
Contraindication/Caution:
Contraindications
Cautions
Pregnancy consideration:
No data is available regarding the usage of this drug during pregnancy.
Breastfeeding warnings:
No data is available regarding the excretion of this drug in breast milk.
Pregnancy category:
Pharmacology:
The pharmacology of lutetium lu 177 vipivotide tetraxetan primarily focuses on its selective targeting of somatostatin receptors on neuroendocrine tumor cells, delivering radiation therapy to these specific tumor sites. By combining the radioactive properties of lutetium lu 177 with the tumor-targeting capabilities of vipivotide tetraxetan, this therapy offers a targeted approach to managing neuroendocrine tumors.
Pharmacodynamics:
The pharmacodynamics of lutetium lu 177 vipivotide tetraxetan are centered around its targeted radiation delivery to somatostatin receptor-positive neuroendocrine tumor cells. By combining the radioactive properties of lutetium lu 177 with the tumor-targeting capabilities of vipivotide tetraxetan, this therapy offers a focused approach to managing neuroendocrine tumors, leading to cell death and tumor regression.
Pharmacokinetics:
Absorption
The peak plasma concentration is 6.58 ng/mL
The AUC is 52.3 ng⋅hr/mL
Distribution
The protein-bound is 60-70%
The volume of distribution is 123L
The time for distribution of the drug is 2.5 hours
Metabolism
It is not metabolized in the body.
Elimination and Excretion
The elimination half-life is approximately 41.6%
The rate of clearance is 2.04 L/hr
Administration:
lutetium lu 177 vipivotide tetraxetan is administered as an intravenous injection. A healthcare provider will insert a needle into a vein, typically in the arm, and slowly inject the radiopharmaceutical into the bloodstream. The injection process usually takes a few minutes.
After the injection, the patient is monitored briefly to ensure no immediate adverse reactions or complications. Patients are typically instructed to report any discomfort or adverse effects they experience during this period.
Patient information leaflet
Generic Name: lutetium lu 177 vipivotide tetraxetan
Pronounced: loo-TEE-shee-um-loo-177 vye-PIV-oh-tide-te-TRAX-e-tan
Why do we use lutetium lu 177 vipivotide tetraxetan?
lutetium lu 177 vipivotide tetraxetan is used to treat certain types of neuroendocrine tumors, particularly those originating in the gastroenteropancreatic system It is also used to treat castration-resistant prostate cancer.
Both our subscription plans include Free CME/CPD AMA PRA Category 1 credits.
On course completion, you will receive a full-sized presentation quality digital certificate.
A dynamic medical simulation platform designed to train healthcare professionals and students to effectively run code situations through an immersive hands-on experience in a live, interactive 3D environment.
When you have your licenses, certificates and CMEs in one place, it's easier to track your career growth. You can easily share these with hospitals as well, using your medtigo app.
